The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The management of MPNs in young patients: transitioning from pediatric to adult care
In this video, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, briefly discusses key considerations in the management of young patients with classical myeloproliferative neoplasms (MPNs), emphasizing the importance of supporting their transition from pediatric to adult care. Prof. Kiladjian stresses that young adults should receive appropriate care and tools to manage the significant long-term impacts of their disease. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
MPNs are quite rare in younger age, but they are more and more frequently diagnosed. Maybe they were undiagnosed or underdiagnosed before, and now with more awareness of these diseases, we see more and more young patients coming to the adult hematologist. And this transition between pediatrician and adults should be done carefully. And we made a kind of proposal of recommendations with an international group of colleagues that was published in Leukemia recently to help the pediatrician give the tools for their patients to switch to adult hematologists...
MPNs are quite rare in younger age, but they are more and more frequently diagnosed. Maybe they were undiagnosed or underdiagnosed before, and now with more awareness of these diseases, we see more and more young patients coming to the adult hematologist. And this transition between pediatrician and adults should be done carefully. And we made a kind of proposal of recommendations with an international group of colleagues that was published in Leukemia recently to help the pediatrician give the tools for their patients to switch to adult hematologists. Why is it important? Because I think these diseases have some impact on the life of these patients. First, there are chronic diseases and it’s always difficult in young patients to manage chronic diseases, especially if you need to take a drug every day. Second, they also have complications that may impact their long-term life, like thrombotic complications, risk of transformation to myelofibrosis, myelodysplastic syndrome, or acute leukemia. And we’ve shown with a large collaborative study we did with the EHA Scientific Working Group on MPNs and European colleagues on a large number of patients, that these patients have the same risk as all the patients to evolve, meaning that after 10 to 20 years, a significant proportion of them will develop acute leukemia, for example, or myelodysplasia. And this is not a small issue when you are diagnosed at 20 years of age, meaning at 40 years you have this risk compared to when you are diagnosed at 70, and then this is maybe less important. So this is a population that needs particular care and particular awareness on how to manage them and help them to go through their life and their disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
